Cite
HARVARD Citation
Perez-Molina, J. et al. (n.d.). Dual treatment with atazanavir–ritonavir plus lamivudine versus triple treatment with atazanavir–ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial. Lancet infectious diseases. 15 (7), pp. 775-784. [Online].